Blue Trust Inc. Grows Position in Amedisys, Inc. (NASDAQ:AMED)

Blue Trust Inc. boosted its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 55.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 349 shares of the health services provider’s stock after purchasing an additional 124 shares during the period. Blue Trust Inc.’s holdings in Amedisys were worth $34,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. HBW Advisory Services LLC purchased a new position in shares of Amedisys during the fourth quarter valued at approximately $38,000. Versant Capital Management Inc lifted its stake in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the last quarter. KBC Group NV bought a new stake in shares of Amedisys during the 3rd quarter worth approximately $63,000. R Squared Ltd purchased a new position in Amedisys during the 4th quarter valued at $203,000. Finally, Impact Partnership Wealth LLC bought a new position in Amedisys in the 4th quarter valued at $226,000. 94.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Stephens reiterated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $100.75.

Amedisys Stock Performance

Amedisys stock opened at $91.57 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market capitalization of $3.00 billion, a PE ratio of 36.34, a P/E/G ratio of 1.78 and a beta of 0.73. The company has a 50 day moving average price of $91.26 and a 200-day moving average price of $93.25. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95.

Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. As a group, equities analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.